AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen® Recipients
This award recognizes a scientist whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer.
2017 Award Recipient
Nicholas C. Turner, PhD, FRCP
Institute of Cancer Research and Royal Marsden
The AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen®, recognizes an investigator of no more than 50 years of age whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer. Such work may involve any discipline across the continuum of biomedical research, including basic, translational, clinical and epidemiological studies.
Dr. Nicholas C. Turner is honored for his seminal work in developing novel targeted therapy approaches for breast cancer, and directing treatment with circulating tumor DNA analysis.
His work on targeted therapies in breast cancer has focused on amplification of FGFR1/2 and targeting the cell cycle for therapy. He identified FGFR1 and FGFR2 amplification as oncogenic drivers that promote endocrine resistance, demonstrating that high-level and clonal amplification are required for response to FGFR inhibitors in the clinic. He has had a major role in targeting abberent regulation of the cell cycle for breast cancer treatment, discovering mechanisms of action of WEE1 inhibitors and CDK4/6 inhibitors, and he has led translational efforts, turning insights from basic science into clinical trials of targeted therapy in breast cancer.
His work on circulating tumor DNA (ctDNA) analysis has demonstrated how ctDNA analysis can more accurately deliver treatment in breast cancer. In particular, he has shown that ctDNA analysis can detect minimal residual disease, and, as well, predict who will relapse after treatment for early stage breast cancer. His work has also demonstrated the potential clinical utility of ctDNA analysis in advanced breast cancer.
Dr. Nicholas Turner is professor at the Institute of Cancer Research and consultant medical oncologist at the Royal Marsden Hospital, in London. He leads the Molecular Oncology at the Breast Cancer Now Research Centre at the Institute of Cancer Research (ICR), and is the Geneotype, Phenotype and Cancer Evolution Lead for The Royal Marsden NIHR Biomedical Research Centre. He is the Breast Domain Lead of the Genomics England Clinical Interpretation Partnerships, and has co-chaired of the ASCO/CAP review committee on circulating tumor DNA analysis in patients with cancer.
- 2017: Nicholas C. Turner
- 2016: Fergus J. Couch
- 2015: Mohamed Bentires-Alj
- 2014: Yiban Kang
- 2013: Jason S. Carroll
- 2012: Kornelia Polyak
- 2011: Ramon E. Parsons
- 2010: Klaus Pantel
- 2009: Charles M. Perou
- 2008: Douglas Easton